188 related articles for article (PubMed ID: 33857233)
1. The economic burden of cervical cancer in Eswatini: Societal perspective.
Ngcamphalala C; Östensson E; Ginindza TG
PLoS One; 2021; 16(4):e0250113. PubMed ID: 33857233
[TBL] [Abstract][Full Text] [Related]
2. The economic burden of human papillomavirus-related precancers and cancers in Sweden.
Östensson E; Silfverschiöld M; Greiff L; Asciutto C; Wennerberg J; Lydrup ML; Håkansson U; Sparén P; Borgfeldt C
PLoS One; 2017; 12(6):e0179520. PubMed ID: 28651012
[TBL] [Abstract][Full Text] [Related]
3. The economic burden of prostate cancer in Eswatini.
Ngcamphalala C; Östensson E; Ginindza TG
BMC Health Serv Res; 2022 Apr; 22(1):483. PubMed ID: 35410213
[TBL] [Abstract][Full Text] [Related]
4. Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination.
Östensson E; Fröberg M; Leval A; Hellström AC; Bäcklund M; Zethraeus N; Andersson S
PLoS One; 2015; 10(9):e0139062. PubMed ID: 26398189
[TBL] [Abstract][Full Text] [Related]
5. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
Aljunid S; Zafar A; Saperi S; Amrizal M
Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths.
Van Kriekinge G; Castellsagué X; Cibula D; Demarteau N
Vaccine; 2014 Feb; 32(6):733-9. PubMed ID: 24291200
[TBL] [Abstract][Full Text] [Related]
7. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature.
Insinga RP; Dasbach EJ; Elbasha EH
Pharmacoeconomics; 2005; 23(11):1107-22. PubMed ID: 16277547
[TBL] [Abstract][Full Text] [Related]
8. Annual national direct and indirect cost estimates of the prevention and treatment of cervical cancer in Brazil.
Novaes HM; Itria A; Silva GA; Sartori AM; Rama CH; Soárez PC
Clinics (Sao Paulo); 2015 Apr; 70(4):289-95. PubMed ID: 26017797
[TBL] [Abstract][Full Text] [Related]
9. Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries.
Termrungruanglert W; Havanond P; Khemapech N; Lertmaharit S; Pongpanich S; Khorprasert C; Taneepanichskul S
Value Health; 2012; 15(1 Suppl):S29-34. PubMed ID: 22265063
[TBL] [Abstract][Full Text] [Related]
10. Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland.
Ginindza TG; Sartorius B; Dlamini X; Östensson E
PLoS One; 2017; 12(5):e0177762. PubMed ID: 28531205
[TBL] [Abstract][Full Text] [Related]
11. [Cervical cancer screening and associated treatment costs in France].
Bergeron C; Breugelmans JG; Bouée S; Lorans C; Bénard S; Rémy V
Gynecol Obstet Fertil; 2006 Nov; 34(11):1036-42. PubMed ID: 17070085
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of cervical cancer from diagnosis to one year after final discharge in Henan Province, China: A retrospective case series study.
Wu Q; Jia M; Chen H; Zhang S; Liu Y; Prem K; Qian M; Yu H
PLoS One; 2020; 15(5):e0232129. PubMed ID: 32379783
[TBL] [Abstract][Full Text] [Related]
13. Economic Burden of Cervical Cancer in Bulgaria.
Lebanova H; Stoev S; Naseva E; Getova V; Wang W; Sabale U; Petrova E
Int J Environ Res Public Health; 2023 Feb; 20(3):. PubMed ID: 36768109
[TBL] [Abstract][Full Text] [Related]
14. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
15. The healthcare costs of treating human papillomavirus-related cancers in Norway.
Hylin H; Thrane H; Pedersen K; Kristiansen IS; Burger EA
BMC Cancer; 2019 May; 19(1):426. PubMed ID: 31064346
[TBL] [Abstract][Full Text] [Related]
16. The burden and costs of prevention and management of genital disease caused by HPV in women: a population-based registry study in Finland.
Salo H; Leino T; Kilpi T; Auranen K; Tiihonen P; Lehtinen M; Vänskä S; Linna M; Nieminen P
Int J Cancer; 2013 Sep; 133(6):1459-69. PubMed ID: 23463194
[TBL] [Abstract][Full Text] [Related]
17. The Cost of Locally Advanced Cervical Cancer in Thailand: an Empirical Study for Economic Analysis.
Katanyoo K; Riewpaiboon A; Chaikledkaew U; Thavorncharoensap M
Asian Pac J Cancer Prev; 2021 Oct; 22(10):3171-3179. PubMed ID: 34710993
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.
Demarteau N; Tang CH; Chen HC; Chen CJ; Van Kriekinge G
Value Health; 2012; 15(5):622-31. PubMed ID: 22867770
[TBL] [Abstract][Full Text] [Related]
19. Reimbursed Costs of Management of Uterine Cervical Lesions in Poland--a Descriptive Analysis of Data from the National Health Fund and the Ministry of Health.
Nowakowski A; Śliwczyński A; Seroczyński P; Cybulski M; Teter Z
Cent Eur J Public Health; 2016 Jun; 24(2):163-8. PubMed ID: 27178030
[TBL] [Abstract][Full Text] [Related]
20. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity.
Soergel P; Makowski L; Schippert C; Staboulidou I; Hille U; Hillemanns P
Hum Vaccin Immunother; 2012 Feb; 8(2):243-51. PubMed ID: 22426367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
